1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Celsius closed a transaction with PepsiCo on August 28, 2025, receiving $585.0 million in cash for 390,000 shares of new Series B Convertible Preferred Stock and acquiring the Rockstar Energy brand in the U.S. and Canada. The deal also gives PepsiCo board designation rights, adds Michael Del Pozzo to the board, and sets up a distribution arrangement covering Alani Nu and Rockstar Energy products, which shareholders should weigh against the dilution and governance rights that come with the preferred stock.
Series B Preferred Stock sold to PepsiCo for $585.0 million in cash; each share is initially convertible into 11,304,348 shares of common stock
Rockstar Energy brand in the U.S. and Canada acquired from PepsiCo under a transaction agreement; the Captaincy also commenced on the Closing Date
PepsiCo may designate two board members, and Michael Del Pozzo was appointed as the second PepsiCo designee, expanding the board from nine to 10 members
Original Purchase Agreement terminated on the Closing Date, August 28, 2025
Exelixis said its board appointed Dana T. Aftab, Ph.D., currently Chief Scientific Officer, as Executive Vice President, Research and Development, effective August 29, 2025. The filing also states that Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer on the same date, and that she is entitled to payments under the company's Change in Control and Severance Benefit Plan. The changes affect the company's senior research and medical leadership, and the filing does not disclose the amount of Dr. Peterson's payments.
Dana T. Aftab, Ph.D., appointed Executive Vice President, Research and Development, effective August 29, 2025
Aftab was previously Executive Vice President, Discovery and Translational Research and Chief Scientific Officer
Amy C. Peterson, M.D., concluded service as EVP, Product Development and Medical Affairs and Chief Medical Officer effective August 29, 2025
Peterson is entitled to payments under the Change in Control and Severance Benefit Plan; amounts not disclosed in the filing
Chemours Chair Dawn Farrell notified the board on August 29, 2025, that she will resign effective September 2, 2025, to become CEO of Canada's newly created Major Projects Office. The board has not yet chosen a successor as chair and said an announcement will follow, so shareholders will be watching for who leads the board.
Dawn Farrell resigns as Chair and from the Board effective September 2, 2025
Farrell is accepting appointment as CEO of the Major Projects Office launched by the Prime Minister of Canada under the Building Canada Act
No successor as Board Chair has been named; the company says an announcement will be forthcoming
Sarepta Therapeutics exchanged $700.0 million of its 1.25% convertible notes due 2027 for $602.0 million of new 4.875% convertible notes due 2030, 5,851,693 shares of common stock and about $123.3 million in cash. The new notes were issued August 28, 2025, and the company also sold 1,106,806 shares to J. Wood Capital Advisors LLC at $18.07 per share, so shareholders face a new debt obligation alongside potential dilution from share issuance and conversion.
Exchanged $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due September 1, 2030, plus 5,851,693 shares and about $123.3 million in cash
New notes have an initial conversion price of about $60.00 per share, versus $20.58 last reported sale price on August 20, 2025
Interest is payable March 1 and September 1 each year, beginning March 1, 2026
Concurrent private placement of 1,106,806 shares to J. Wood Capital Advisors LLC at $18.07 per share
Directors Tracy A. Bolt and A. Haag Sherman resigned from Hilltop Holdings' Board of Directors effective immediately on August 27, 2025. The filing states their resignations were not the result of any disagreement with the company on its operations, policies or practices. On August 29, 2025, the board appointed J. Taylor Crandall as Lead Independent Director.
Tracy A. Bolt and A. Haag Sherman resigned from the board on August 27, 2025, effective immediately
The filing states the resignations were not due to any disagreement with the company
J. Taylor Crandall was appointed Lead Independent Director on August 29, 2025
At its August 27, 2025 annual meeting, Rocket Lab's stockholders re-elected no one new but elected three Class I directors, ratified Deloitte & Touche as auditor, and approved the executive pay advisory vote. They did not approve an amendment to remove a recently added pass-through voting provision at subsidiary Rocket Lab USA, Inc., because it did not reach the required 66-2/3% of voting power. The company also adopted a Senior Executive Cash Incentive Bonus Plan on August 25, 2025.
Stockholders elected Jon Olson, Merline Saintil and Alex Slusky as Class I directors for terms expiring at the 2028 annual meeting.
The charter amendment for Rocket Lab USA, Inc. received 298,079,255 votes for and 1,925,556 against, short of the required 66-2/3% of voting power.
Compensation Committee adopted the Senior Executive Cash Incentive Bonus Plan on August 25, 2025; the full plan is filed as Exhibit 10.1.
Stockholders approved the named executive officer compensation on an advisory basis, with 240,340,772 votes for and 58,526,365 against.
McKinley Acquisition Corporation filed an 8-K to report that it completed its initial public offering of 15,000,000 units at $10.00 per unit, generating $150 million in gross proceeds, plus a private placement of 465,000 units. The $150 million was deposited in a trust account for public shareholders, and the auditor's report includes a going concern warning, stating that the company lacks the capital to fund operations for a reasonable period and that there is substantial doubt about its ability to continue. The company has not yet identified a business combination target and must complete one within 18 months of the IPO closing or redeem public shares.
15,000,000 units sold at $10.00 each, generating $150 million in gross proceeds; the IPO closed on August 13, 2025
465,000 private placement units sold at $10.00 each, or $4.65 million, to McKinley Partners LLC, Clear Street LLC and Brookline Capital Markets, with $500,000 not yet received
$150 million deposited in the trust account for public shareholders as of August 13, 2025; the company has 18 months to complete an initial business combination
CBIZ CPAs P.C. included a going concern explanatory paragraph in its audit report dated August 29, 2025
Greif reported fiscal third-quarter 2025 results, with net income attributable to Greif falling to $64.0 million from $87.1 million a year earlier, mainly due to a $46.1 million gain on the 2024 Delta Petroleum divestiture. Combined Adjusted EBITDA rose 11% to $220.9 million and adjusted free cash flow was $170.7 million, while the company also agreed to sell its timberlands business for $462.0 million and kept its fiscal 2025 guidance of $725 million to $735 million in Combined Adjusted EBITDA.
Net income attributable to Greif fell to $64.0 million, or $1.10 per diluted Class A share, from $87.1 million, or $1.50, a year earlier
Net income excluding adjustments rose 11.6% to $60.4 million, or $1.03 per diluted Class A share, versus $0.92 a year earlier
Combined Adjusted EBITDA rose 11% to $220.9 million; fiscal 2025 outlook is $725 million to $735 million
Agreed sale of timberlands business for $462.0 million to Molpus Woodlands Group, with closing anticipated October 1, 2025
Leggett & Platt completed the sale of its Aerospace Products Group to funds advised by Tinicum Incorporated on August 29, 2025, receiving an estimated $285.8 million in cash at closing, subject to post-closing adjustments. The company also revised its full-year 2025 guidance: sales and adjusted EPS ranges were lowered, while reported EPS ranges were raised because of a $0.60 per share gain on the sale.
Estimated purchase price of $285.8 million paid in cash at closing, subject to customary post-closing adjustments
Company expects after-tax proceeds of approximately $250 million, to be used primarily to pay down debt
2025 sales guidance revised to $3.9 billion to $4.2 billion from $4.0 billion to $4.3 billion, excluding the Aerospace Products Group
2025 adjusted EPS guidance revised to $0.95 to $1.15 from $1.00 to $1.20; reported EPS guidance raised to $1.43 to $1.72 from $0.88 to $1.17
Hope Bancorp disclosed that Steven S. Koh, its Honorary Chairman and a board member, will retire from the board. The filing says the retirement was not the result of any disagreement with the company, and the board is expected to be reduced to 10 directors afterward. The change affects board composition but does not involve the CEO, CFO or a financial result.
Steven S. Koh, Honorary Chairman, will retire from the board; the 8-K gives an effective date of December 1, 2025, while the press release gives December 31, 2025
Mr. Koh served as Honorary Chairman since July 6, 2017, and as the first Chairman of Hope Bancorp from July 29, 2016
The board is expected to be fixed at 10 directors following his retirement
The company states the decision was not the result of any disagreement on operations, policies or practices
Crocs appointed Patraic Reagan, currently CFO of SharkNinja, as Executive Vice President and Chief Financial Officer, effective September 22, 2025, after CFO Susan Healy resigned effective immediately on August 28, 2025. The company also reaffirmed its third quarter 2025 financial outlook, which it had previously disclosed on August 7, 2025.
Patraic Reagan starts September 22, 2025, with an annual base salary of $750,000 and a sign-on bonus of $800,000, which he must repay if he leaves or is terminated for Cause within 12 months.
Reagan receives a $3.5 million equity grant in time-based restricted stock units, vesting in parts from six to 36 months after his start date.
Susan Healy resigned on August 28, 2025, and will serve as Special Advisor until October 31, 2025, with a $400,000 lump sum payable on her separation date and no cash severance.
Crocs reaffirmed its third quarter 2025 outlook and will present at the Goldman Sachs 32nd Annual Global Retailing Conference on September 3, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.